Li
Liomont
Mexico City MXFounded 19383,000 employees
Private CappharmaPrivateOncologyRespiratory
Platform: Mexican Pharma
Market Cap
N/A
All Drugs
4
Clinical Trials
6
Failed / Terminated
2
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Nidanesiran | LIO-2443 | Preclinical | 1 | RET | HNSCCTTR Amyloidosis | ||
| Tezetenlimab | LIO-3140 | Phase 2 | 2 | PD-1 | MGPSP | ||
| Elraosocimab | LIO-7166 | Phase 3 | 1 | Cl18.2 | PSPHCC | ||
| LIO-530 | LIO-530 | Phase 1 | 2 | CDK2 | PNH |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (6)